Mitsubishi UFJ Asset Management Co. Ltd. Has $90.08 Million Stock Position in Kenvue Inc. $KVUE

Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Kenvue Inc. (NYSE:KVUE) by 5.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,303,956 shares of the company’s stock after buying an additional 240,596 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Kenvue were worth $90,082,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Evergreen Wealth Solutions LLC lifted its position in Kenvue by 2.6% during the 1st quarter. Evergreen Wealth Solutions LLC now owns 16,769 shares of the company’s stock worth $402,000 after acquiring an additional 432 shares during the last quarter. Wealth Alliance LLC increased its stake in shares of Kenvue by 1.6% in the first quarter. Wealth Alliance LLC now owns 31,778 shares of the company’s stock worth $762,000 after purchasing an additional 486 shares during the period. Everett Harris & Co. CA lifted its position in shares of Kenvue by 1.4% during the 1st quarter. Everett Harris & Co. CA now owns 36,971 shares of the company’s stock worth $887,000 after purchasing an additional 500 shares during the last quarter. Proffitt & Goodson Inc. lifted its position in shares of Kenvue by 8.2% during the 2nd quarter. Proffitt & Goodson Inc. now owns 6,831 shares of the company’s stock worth $143,000 after purchasing an additional 517 shares during the last quarter. Finally, UMB Bank n.a. boosted its stake in Kenvue by 22.3% during the 2nd quarter. UMB Bank n.a. now owns 2,853 shares of the company’s stock valued at $60,000 after purchasing an additional 521 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Up 2.6%

Shares of KVUE stock opened at $16.90 on Monday. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. The stock has a fifty day moving average price of $16.76 and a 200 day moving average price of $20.26. The stock has a market cap of $32.37 billion, a P/E ratio of 22.53, a price-to-earnings-growth ratio of 2.46 and a beta of 0.71.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The business’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th will be paid a dividend of $0.2075 per share. The ex-dividend date is Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a yield of 4.9%. Kenvue’s dividend payout ratio (DPR) is currently 110.67%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of several recent analyst reports. Zacks Research raised Kenvue to a “strong sell” rating in a research report on Monday, August 11th. The Goldman Sachs Group dropped their target price on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, October 2nd. Royal Bank Of Canada cut their target price on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research note on Friday, August 8th. Johnson Rice restated a “neutral” rating on shares of Kenvue in a research report on Tuesday, October 28th. Finally, Evercore ISI set a $18.00 price objective on shares of Kenvue in a report on Tuesday, October 28th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average price target of $20.17.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.